These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 38390682)
1. Reciprocal relationship between cancer stem cells and myeloid-derived suppressor cells: implications for tumor progression and therapeutic strategies. Ding G; Yu H; Jin J; Qiao X; Ma J; Zhang T; Cheng X Future Oncol; 2024 Feb; 20(4):215-228. PubMed ID: 38390682 [TBL] [Abstract][Full Text] [Related]
2. MDSCs might be "Achilles heel" for eradicating CSCs. Yang T; Liang N; Li J; Hu P; Huang Q; Zhao Z; Wang Q; Zhang H Cytokine Growth Factor Rev; 2022 Jun; 65():39-50. PubMed ID: 35595600 [TBL] [Abstract][Full Text] [Related]
3. Mutualistic Effects of the Myeloid-Derived Suppressor Cells and Cancer Stem Cells in the Tumor Microenvironment. Tanriover G; Aytac G Crit Rev Oncog; 2019; 24(1):61-67. PubMed ID: 31679221 [TBL] [Abstract][Full Text] [Related]
4. Myeloid-derived suppressor cells endow stem-like qualities to multiple myeloma cells by inducing piRNA-823 expression and DNMT3B activation. Ai L; Mu S; Sun C; Fan F; Yan H; Qin Y; Cui G; Wang Y; Guo T; Mei H; Wang H; Hu Y Mol Cancer; 2019 Apr; 18(1):88. PubMed ID: 30979371 [TBL] [Abstract][Full Text] [Related]
6. Targeting Myeloid-Derived Suppressor Cells to Enhance the Antitumor Efficacy of Immune Checkpoint Blockade Therapy. Li X; Zhong J; Deng X; Guo X; Lu Y; Lin J; Huang X; Wang C Front Immunol; 2021; 12():754196. PubMed ID: 35003065 [TBL] [Abstract][Full Text] [Related]
7. Myeloid-derived suppressor cells promote epithelial ovarian cancer cell stemness by inducing the CSF2/p-STAT3 signalling pathway. Li X; Wang J; Wu W; Gao H; Liu N; Zhan G; Li L; Han L; Guo X FEBS J; 2020 Dec; 287(23):5218-5235. PubMed ID: 32239647 [TBL] [Abstract][Full Text] [Related]
8. CAFs shape myeloid-derived suppressor cells to promote stemness of intrahepatic cholangiocarcinoma through 5-lipoxygenase. Lin Y; Cai Q; Chen Y; Shi T; Liu W; Mao L; Deng B; Ying Z; Gao Y; Luo H; Yang X; Huang X; Shi Y; He R Hepatology; 2022 Jan; 75(1):28-42. PubMed ID: 34387870 [TBL] [Abstract][Full Text] [Related]
9. Exploring the dynamic interplay between cancer stem cells and the tumor microenvironment: implications for novel therapeutic strategies. Li YR; Fang Y; Lyu Z; Zhu Y; Yang L J Transl Med; 2023 Oct; 21(1):686. PubMed ID: 37784157 [TBL] [Abstract][Full Text] [Related]
10. The Role of Myeloid-Derived Suppressor Cells in Tumor Growth and Metastasis. Bayik D; Lee J; Lathia JD Exp Suppl; 2022; 113():189-217. PubMed ID: 35165865 [TBL] [Abstract][Full Text] [Related]
11. Inhibitory effect of ginsenoside Rg3 on cancer stemness and mesenchymal transition in breast cancer via regulation of myeloid-derived suppressor cells. Song JH; Eum DY; Park SY; Jin YH; Shim JW; Park SJ; Kim MY; Park SJ; Heo K; Choi YJ PLoS One; 2020; 15(10):e0240533. PubMed ID: 33091036 [TBL] [Abstract][Full Text] [Related]
12. Tumor Microenvironment: A Niche for Cancer Stem Cell Immunotherapy. Borlongan MC; Saha D; Wang H Stem Cell Rev Rep; 2024 Jan; 20(1):3-24. PubMed ID: 37861969 [TBL] [Abstract][Full Text] [Related]
13. Targeting the crosstalk between cytokine-induced killer cells and myeloid-derived suppressor cells in hepatocellular carcinoma. Yu SJ; Ma C; Heinrich B; Brown ZJ; Sandhu M; Zhang Q; Fu Q; Agdashian D; Rosato U; Korangy F; Greten TF J Hepatol; 2019 Mar; 70(3):449-457. PubMed ID: 30414862 [TBL] [Abstract][Full Text] [Related]
14. The immunobiology of myeloid-derived suppressor cells in cancer. Motallebnezhad M; Jadidi-Niaragh F; Qamsari ES; Bagheri S; Gharibi T; Yousefi M Tumour Biol; 2016 Feb; 37(2):1387-406. PubMed ID: 26611648 [TBL] [Abstract][Full Text] [Related]
15. Tumor-derived exosomes, myeloid-derived suppressor cells, and tumor microenvironment. Tian X; Shen H; Li Z; Wang T; Wang S J Hematol Oncol; 2019 Aug; 12(1):84. PubMed ID: 31438991 [TBL] [Abstract][Full Text] [Related]
16. The immunomodulatory role of exosomal microRNA networks in the crosstalk between tumor-associated myeloid-derived suppressor cells and tumor cells. Shokati E; Safari E Int Immunopharmacol; 2023 Jul; 120():110267. PubMed ID: 37276829 [TBL] [Abstract][Full Text] [Related]
17. Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer. Li K; Shi H; Zhang B; Ou X; Ma Q; Chen Y; Shu P; Li D; Wang Y Signal Transduct Target Ther; 2021 Oct; 6(1):362. PubMed ID: 34620838 [TBL] [Abstract][Full Text] [Related]
18. Myeloid-Derived Suppressor Cells in the Tumor Microenvironment. Dysthe M; Parihar R Adv Exp Med Biol; 2020; 1224():117-140. PubMed ID: 32036608 [TBL] [Abstract][Full Text] [Related]
19. Specific targeting of cancer stem cells by immunotherapy: A possible stratagem to restrain cancer recurrence and metastasis. Singh D; Khan MA; Siddique HR Biochem Pharmacol; 2022 Apr; 198():114955. PubMed ID: 35181312 [TBL] [Abstract][Full Text] [Related]
20. Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer. Panni RZ; Sanford DE; Belt BA; Mitchem JB; Worley LA; Goetz BD; Mukherjee P; Wang-Gillam A; Link DC; Denardo DG; Goedegebuure SP; Linehan DC Cancer Immunol Immunother; 2014 May; 63(5):513-28. PubMed ID: 24652403 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]